Tibor Keler - 07 Dec 2022 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
EXECUTIVE VP & CSO
Signature
/s/ Samuel B. Martin, attorney-in-fact for Tibor Keler
Issuer symbol
CLDX
Transactions as of
07 Dec 2022
Net transactions value
-$575,740
Form type
4
Filing time
09 Dec 2022, 15:07:21 UTC
Previous filing
17 Jun 2022
Next filing
20 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock, par value $0.001 per share Options Exercise $46,871 +16,860 +229% $2.78* 24,217 07 Dec 2022 Direct
transaction CLDX Common Stock, par value $0.001 per share Sale $622,611 -16,860 -70% $36.93 7,357 07 Dec 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (right to buy) Options Exercise $0 -16,860 -28% $0.000000 43,140 07 Dec 2022 Common Stock 16,860 $2.78 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.69 to $37.28 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F2 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.